(c) 2024 PillSync.com

Dexmethylphenidate hydrochloride 24 HR dexmethylphenidate hydrochloride 15 MG Extended Release Oral Capsule

1 INDICATIONS AND USAGE Dexmethylphenidate hydrochloride extended-release capsules are indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in patients aged 6 years and older. The effectiveness of dexmethylphenidate hydrochloride extended-release in the treatment of ADHD in patients aged 6 years and older was established in 2 placebo-controlled studies in patients meeting DSM-IV criteria for ADHD [see Clinical Studies (14) ]. A diagnosis of Attention Deficit Hyperactivity Disorder (ADHD; DSM-IV) implies the presence of hyperactive-impulsive or inattentive symptoms that caused impairment and were present before age 7 years. The symptoms must cause clinically significant impairment, e.g., in social, academic, or occupational functioning, and be present in 2 or more settings, e.g., school (or work) and at home. The symptoms must not be better accounted for by another mental disorder. For the Inattentive Type, at least 6 of the following symptoms must have persisted for at least 6 months: lack of attention to details/careless mistakes; lack of sustained attention; poor listener; failure to follow through on tasks; poor organization; avoids tasks requiring sustained mental effort; loses things; easily distracted; forgetful. For the Hyperactive-Impulsive Type, at least 6 of the following symptoms must have persisted for at least 6 months: fidgeting/squirming; leaving seat; inappropriate running/climbing; difficulty with quiet activities; “on the go”; excessive talking; blurting answers; can’t wait turn; intrusive. The Combined Types requires both inattentive and hyperactive-impulsive criteria to be met. Special Diagnostic Considerations Specific etiology of this syndrome is unknown, and there is no single diagnostic test. Adequate diagnosis requires the use not only of medical but of special psychological, educational, and social resources. Learning may or may not be impaired. The diagnosis must be based upon a complete history and evaluation of the child and not solely on the presence of the required number of DSM-IV characteristics. Need for Comprehensive Treatment Program Dexmethylphenidate hydrochloride extended-release capsules are indicated as an integral part of a total treatment program for ADHD that may include other measures (psychological, educational, social) for patients with this syndrome. Drug treatment may not be indicated for all children with this syndrome. Stimulants are not intended for use in the child who exhibits symptoms secondary to environmental factors and/or other primary psychiatric disorders, including psychosis. Appropriate educational placement is essential and psychosocial intervention is often helpful. When remedial measures alone are insufficient, the decision to prescribe stimulant medication will depend upon the physician’s assessment of the chronicity and severity of the child’s symptoms. Long-Term Use The effectiveness of dexmethylphenidate hydrochloride extended-release for long-term use, i.e., for more than 7 weeks, has not been systematically evaluated in controlled trials. Therefore, the physician who elects to use dexmethylphenidate hydrochloride extended-release for extended periods should periodically reevaluate the long-term usefulness of the drug for the individual patient [see Dosage and Administration (2.3) ]. Dexmethylphenidate hydrochloride extended-release is a CNS stimulant indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in patients aged 6 years and older. ( 1 )

Actavis Pharma, Inc.


5 years ago CAPSULE PINK 806 Dexmethylphenidate hydrochloride  24 HR dexmethylphenidate hydrochloride 15 MG Extended Release Oral Capsule

CAPSULE PINK 806

5 years ago CAPSULE PINK 806 Dexmethylphenidate hydrochloride  24 HR dexmethylphenidate hydrochloride 15 MG Extended Release Oral Capsule

806 CAPSULE PINK

16 HOW SUPPLIED/STORAGE AND HANDLING Dexmethylphenidate hydrochloride extended-release capsules contain white to off-white pellets and are available as follows: 5 mg – Size 2 capsule with white opaque body and light purple opaque cap printed with and 804 in black ink on both cap and body. capsules are supplied in bottles of 100 (NDC 45963-804-11). 10 mg - Size 2 capsule with white opaque body and dark purple opaque cap printed with and 805 in black ink on both cap and body. capsules are supplied in bottles of 100 (NDC 45963-805-11). 15 mg - Size 2 capsule with white opaque body and light pink opaque cap printed with and 806 in black ink on both cap and body. capsules are supplied in bottles of 100 (NDC 45963-806-11). 20 mg - Size 0 capsule with white opaque body and dark pink opaque cap printed with and 807 in black ink on both cap and body. capsules are supplied in bottles of 100 (NDC 45963-807-11). 30 mg - Size 00 capsule with white opaque cap and body printed with and 833 in black ink on both cap and body. capsules are supplied in bottles of 100 (NDC 45963-833-11). Store at 25°C (77°F); excursions permitted to 15° to 30°C (59° to 86°F). [See USP Controlled Room Temperature]. Dispense in a tight, light-resistant container as defined in the USP. 1 1 1 1 32f71710-figure-03


More pills like CAPSULE 806












DISCLAIMER:

"This tool does not provide medical advice, and is for informational and educational purposes only, and is not a substitute for professional medical advice, treatment or diagnosis. Call your doctor to receive medical advice. If you think you may have a medical emergency, please dial 911."

"Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service."

"This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product."

PillSync may earn a commission via links on our site